Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS5133 in advanced solid tumors
NCT07061639Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of QLS5133 in solid tumor (advanced stage) (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Incidence and severity of adverse events and serious adverse events at 2 years, Maximum tolerated dose at 28 days and 2 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QLS5133
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07061639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061639.